4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cardiomyopathy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 311 ongoing clinical trials involving Cardiomyopathy
Of the 311 trials,109 trials are in Phase III
Furthermore, 88 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Cardiomyopathy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cardiomyopathy, a cardiovascular indication. The largest number of ongoing clinical trials for Cardiomyopathy is conducted in the Europe region. Asia-Pacific and North America are among some of the other prominent regions involved in Cardiomyopathy-related drug trials.

MyoKardia Inc: The leading ongoing Cardiomyopathy related clinical trial sponsor

MyoKardia Incis the top sponsor for Cardiomyopathy-related ongoing clinical trials.

Novartis AG, Montreal Heart Institute, and Sapienza University of Romeare a few other notable clinical trial sponsors involved inCardiomyopathy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cardiomyopathy

Amiodarone hydrochloride (Atlansil, Arycor, Amiodarone, Cordarone X, Trangorex, Amiodirex, Cordarone, Amidacore), Carvedilol (Artist/ Coreg/ Carzec/ Dilatrend/ Eucardic/ Kredex), and Ivabradine hydrochloride (Procoralan/Corlentor, Coralan) are among the key marketed drugs involving Cardiomyopathy.

Amiodarone hydrochloride (Atlansil, Arycor, Amiodarone, Cordarone X, Trangorex, Amiodirex, Cordarone, Amidacore) is an antianginal and antiarrhythmic agent. It functions via Alpha 1 Adrenergic Receptor (ADRA1) Antagonist; Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist; Calcium Channel Blocker; Potassium Channel (KCN) Blocker; Sodium Channel Blocker mechanism of action. It is formulated as tablets for oral and injectable solution for intravenous route of administration. Cordarone is marketed for the treatment of Cardiomyopathy and several other indications including ventricular arrhythmia, atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, tachycardia (tachyarrhythmias), supraventricular tachycardia, ventricular tachycardia and wolff-parkinson-white syndrome. It was first approved in 1967 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Sanofi, and Zentiva Group AS.

Carvedilol (Artist/ Coreg/ Carzec/ Dilatrend/ Eucardic/ Kredex) is a carbazole derivative acts as anti-hypertensive agent. It functions via Alpha 1 Adrenergic Receptor (ADRA1) Antagonist; Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist; Beta 2 Adrenergic Receptor (Beta 2 Adrenoreceptor or ADRB2) Antagonist mechanism of action. It is formulated as tablets or film coated tablets for oral route of administration. Carvedilol is marketed for the treatment of Cardiomyopathy and several other indications including Angina (Angina Pectoris), Hypertension, Myocardial Infarction, Congenital Heart Disease, Tachycardia (Tachyarrhythmias), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Myocardial Ischemia, Congestive Heart Failure (Heart Failure), Left Ventricular Dysfunction, and Unstable Angina. Carvedilol was first approved in 1990 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including GlaxoSmithKline Plc, Daiichi Sankyo Co Ltd, and F. Hoffmann-La Roche Ltd.